NeoGenomics operate a network of cancer-focused testing laboratories in the U.S., Europe and Asia. Co.'s testing services include the following: Cytogenetics (karyotype analysis), a study of chromosomes and their relationship to disease; Fluorescence In-Situ Hybridization, a molecular cytogenetic technique that focuses on detecting and localizing the presence or absence of specific DNA sequences and genes on chromosomes; Flow cytometry, a technique utilized to measure the characteristics of cell populations; Immunohistochemistry and Digital Imaging; Molecular testing; and Morphologic analysis, a process of analyzing cells under the microscope. When considering the NeoGenomics Inc stock dividend history, we have taken known splits into account, such that the NEO dividend history is presented on a split-adjusted ("apples to apples") basis. NeoGenomics Inc dividend history is presented both in graphical/chart form, and as a NEO dividend history data table along the right-hand column.
|
NEO Stock Dividend HistoryThe NEO dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable NEO historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the NEO dividend history record. Also see the NEO stock dividend history data table along the right-hand column below. |
|
|
Buy (3.46 out of 4) 58th percentile
(ranked higher than approx. 58% of all stocks covered)
Analysts' Target Price: NEO Forecast Based on data provided by Zacks Investment Research via Quandl.com |